Skip to main content

Filed under:

Theranos: the latest news about the controversial blood-testing startup

Share this story

Theranos, a blood-testing startup that's been valued at $9 billion, has recently drawn criticism for using unvetted proprietary tech, misleading public officials, and using a regulatory loophole to avoid getting its tests approved by the FDA. Now, regulators are considering banning Theranos CEO Elizabeth Holmes from owning and operating a lab for at least two years.